Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have allowed the biotechnology industry to deliver on the promise of targeted cancer drugs. Today, there are more than 150 companies developing more than 260 protein kinase inhibitory drugs in more than 450 clinical trials targeting around 45 different cancer indications. The number of protein kinase targets has increased to over 50 different molecular targets in just a few years. BioSeeker has captured all these in Protein Kinase Inhibitors in Oncology: Drug Pipeline Update 2007.
Strategic Outlook on Protein Kinase Inhibitors in Onoclogy is the market analysis report. Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development. Understand the clinical and strategic challenges to the commercialization of protein kinase inhibitor treatments and assess opportunities and risks for the continued development of innovative developmental treatments.
Find out more about each product by clicking on respective links.
